Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

FINAL PX TALK/SIZING: Douglas E1.305bn 5NC2 6% at par; Kirk Beauty E475m 5.5NC2.5 9% at par

HYC European Market: Deal Flow - General

Douglas/Kirk Beauty (DOUGR) EUR1.78bn (up from EUR1.63bn and from EUR1.3bn) 144A/Reg S notes 2-part. Via GS/DB/UniCredit jt glocos/BNP/UBS jt books. No reg rights. List ISE. NY law.

- Douglas GMBH EUR1.305bn (down from EUR1.33bn, up from EUR1bn) sr sec notes due 2026 (5y). NC2 (MWC B+50bp) (50%,25%,par). Equity claw: 2y 40%. Special call: 10% per year the first 2 years at 103. B3/B-/B (stable/negative/stable). IPT: 5.50% at par. Final px talk: 6.00% at par.

- Kirk Beauty SUN GmbH (holdco) EUR475m (up from EUR300m) sr PIK notes due 2026 (5.5y). NC2.5 MWC B+50bp) (50%,25%,par). Equity claw: 2y 40%. Caa2/CCC/CCC (stable/negative/stable). IPT: 9.00% at par. Final px talk: 9.00% at par.

Did investor call at 2pm UKT 03/18. Small group meeting 03/19-24. Books close at 12pm UKT today. Pricing today UK afternoon. UOP: along with a new credit facility for Parfurmerie Douglas International GmbH, consisting of EUR600m (down from EUR750m, and down from EUR1.08bn) sr sec term loan B and EUR170m revolver (lender call 03/16 via GS/DB/Unicredit/UBS joint books), to fund a recap, including redeeming Douglas GmbH EUR300m 6.25% sr sec notes due 07/15/22 (callable at 100) and Kirk Beauty One GmbH EUR335m 8.75% sr notes due 07/15/23 (callable at 100), repay its existing sr sec credit facilities (EUR1.67bn term loan B nd EUR200m drawn on its revolver), and EUR99m cash on the B/S. The equity sponsor CVC is also contributing EUR220m in equity. Biz: European specialist retailer of beauty care and lifestyle products in online shops, the beauty marketplace and 2,400 stores. HQ: Dusseldorf, Germany.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.